Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravesical Contrast-Enhanced MRI for Bladder Cancer Staging
NCT04369560Phase 1Recruiting
- Start
- May 2025
- Primary completion
- Jan 2028
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of gadobutrol and ferumoxytol in bladder cancer. Primary endpoint: Accuracy of MRI assessment of depth of bladder wall penetration at 4 weeks. Started May 2025; status: recruiting.
02
Drugs
gadobutrolferumoxytol
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT04369560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04369560.